I an wait boys and girls!!!!!
Big boys coming to play ball!!!!!!!!
San Diego Tribne:
Pharmaceutical giant Eli Lilly will greatly expand its research center in La Jolla so it can strengthen its already deep collaborations with UC San Diego and the region’s biomedical institutes.
The Indianapolis-based company said its local workforce will grow to 330 from 200, mostly through the addition of scientists who work on autoimmune disorders and other afflictions.
It plans to nearly double its research space to 300,000 square feet by taking over a building that’s being vacated by Qualcomm.
The moves are part of a nationwide research boom by Eli Lilly, whose history includes helping to purify insulin to treat diabetes, mass producing the Salk polio vaccine, introducing the first genetically engineered human insulin and developing medications to fight cancer, depression and osteoporosis. The conglomerate also identified and developed Prozac, a groundbreaking antidepressant.
“We’ve always known that San Diego was a hub for science, but actually having a presence here really brought it to life for us,” said Thomas Bumol, the company’s senior vice president for biotechnology and immunology. “We’ve seen significant advances at (the local biomedical institutes), at UCSD. This has become quite an exciting center for us for collaboration.”
Two years ago, Eli Lilly awarded UC San Diego a $76.6 million grant to help the company carry out clinical trials of a drug aimed at treating Alzheimer’s disease.
In May, the company announced that it will partner with the Sanford Burnham Prebys Medical Discovery Institute in La Jolla to seek out treatments for a variety of autoimmune disorders, including lupus and inflammatory bowel disease.
Those alliances build on Eli Lilly’s roughly 35-year-history in San Diego, which began with the purchase of Hybritech, the county’s first biotech company.
Hybritech faded afterward, and Eli Lilly sold the business several years later. Nevertheless, the initial Hybritech sale established the San Diego model of discovering important new products, building growth-minded companies around them and selling off those businesses for huge profits. Much of the profits are then invested in forming more start-ups.
“Eli Lilly was the pioneer large pharma company in San Diego when it acquired Hybritech ... and has continually demonstrated its confidence in the region over the years, as it has continually increased its research presence through further acquisition of our early stage companies, venture investment and the construction of the facility at Campus Point (Drive) several years ago,” said Joseph Panetta, executive director of the San Diego-based trade group Biocom.
Bumol said his corporation’s interest in this region has risen in recent years as Sanford Burnham and UC San Diego have invested heavily in translational medicine, the burgeoning, national movement of efforts to more quickly transform basic lab discoveries into drugs and other therapies.
Only because the MM are manipulating the price, to get retail out and allow institutions to accumulate. Typical WS crooks doing the same thing with small biotechnology. The SEC gets paid to look the other way and everyone knows this.
Look at the last 50 biotech that got bought out, Institutions owned on average over 90% of the shares.
So they'll tell you the pps is dropping which it has the the cost of borrowing over the last few years has cost Them greatly, make no mistake.
This is the Biotech playbook. 8-12 months, severance packages, layoffs, no real focus on selling drug, no CFO. CEO, or Investment Director-Public Affairs Director.
I wonder what would happen to the Short interest?
Brazil and Mexico approvals expected this year. XR expected this year.
B) They start accumulating real shares versus mass producing fake shares.
C) They pay board hacks to slam BOD character versus disproving the science.
D) They buy and/or sale large 100 blocks early and late into the trading day.
E) They're also aware of the die hard retail that refuse to let there 40% stake go.
If we follow the biotech playbook, Company's doing or did the following in preparation for sale:
1. Let CFO go with parachute. Happened in July 15.
2. Let go all non-essential personnel. happened in Oct 15
3. Let CEO go in Nov 15.
4. Sales of lead drug slide, my assumption getting rid of inventory because XR will be approved.
5. Made small deal/s for to prove capability and viability of technologies are authentic.
The science is irrefutable, ARNA has succeeded where others have failed with the S1p1 receptor. They continue to make ground breaking technologies that are better than the competitors. As you have read in the last few months several of the competitors have tried and failed; too include the companies that where purchased for Billions. So, as a long term investor I will continue to provide updated correct positive information as it is released to the public. I will be a champion for this company letting all my constituents know about this transformative biotech.
I have no time for name calling, retorts to short interest working for HF, and institutions trying to scare shares from retail investors. I don't get paid, I just inform. Unlike the pond #$%$ that write slanderous articles about this company. Your job, as a short hack work for these folks who undermine what real research and business is all about.
Just like your HF buddies eventually you get caught by the SEC or provocative news that shows that the company is making strides for the improvement of the quality of life for people.
I am long ARNA
Manipulation to the extremes.
tutes playbook for biotech.
This is sickening!!!!!!
SEE Movie "THE BIG SHORT.
ownership. They hire these cons and they post non stop for months and yes even years to get you to sale your shares. Just continue to buy more. As the news comes out your shares will take off.
moving to phase II, and did I mention one drug 30% more effective than RCPT which got bought out for 7.3 Billion.